Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Gains from Sales and Divestitures (2022 - 2023)

Historic Gains from Sales and Divestitures for Traws Pharma (TRAW) over the last 2 years, with Q3 2023 value amounting to $43567.0.

  • Traws Pharma's Gains from Sales and Divestitures rose 4317.59% to $43567.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $43567.0, marking a year-over-year increase of 4317.59%. This contributed to the annual value of $30429.0 for FY2022, which is N/A changed from last year.
  • Traws Pharma's Gains from Sales and Divestitures amounted to $43567.0 in Q3 2023, which was up 4317.59% from $43567.0 recorded in Q2 2023.
  • In the past 5 years, Traws Pharma's Gains from Sales and Divestitures registered a high of $43567.0 during Q1 2023, and its lowest value of $30429.0 during Q3 2022.